



DIAGNOSTIC PATHOLOGY

LYMPH NODES AND SPLEEN WITH EXTRANODAL LYMPHOMAS



MEDEIROS

Miranda • Wang • Vega
Muzzafar • Yin
Bueso-Ramos • Lin



DIAGNOSTIC PATHOLOGY

LYMPH NODES AND SPLEEN

WITH EXTRANODAL LYMPHOMAS



L. Jeffrey Medeiros, MD

Professor and Chair

Department of Hematopathology

The University of Texas M. D. Anderson Cancer Center
Houston, TX

Roberto N. Miranda, MD

Associate Professor

Department of Hematopathology

The University of Texas M. D. Anderson Cancer Center
Houston, TX

Sa A. Wang, MD

Assistant Professor

Department of Hematopathology

The University of Texas M. D. Anderson Cancer Center
Houston, TX

Francisco Vega, MD, PhD

Assistant Professor

Department of Hematopathology

The University of Texas M. D. Anderson Cancer Center
Houston, TX

Tariq Muzzafar, MBBS

Assistant Professor

Department of Hematopathology

The University of Texas M. D. Anderson Cancer Center
Houston, TX

C. Cameron Yin, MD, PhD

Assistant Professor

Department of Hematopathology

The University of Texas M. D. Anderson Cancer Center
Houston, TX

Carlos E. Bueso-Ramos, MD, PhD

Professor

Department of Hematopathology

The University of Texas M. D. Anderson Cancer Center
Houston, TX

Pei Lin, MD

Associate Professor

Department of Hematopathology

The University of Texas M. D. Anderson Cancer Center
Houston, TX





AMIRSYS®

Names you know. Content you trust.®

First Edition

© 2011 Amirsys, Inc.

Compilation © 2011 Amirsys Publishing, Inc.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or media or by any means, electronic, mechanical, photocopying, recording, or otherwise, without prior written permission from Amirsys, Inc.

Printed in Canada by Friesens, Altona, Manitoba, Canada

ISBN: 978-1-931884-52-5

Notice and Disclaimer

The information in this product ("Product") is provided as a reference for use by licensed medical professionals and no others. It does not and should not be construed as any form of medical diagnosis or professional medical advice on any matter. Receipt or use of this Product, in whole or in part, does not constitute or create a doctor-patient, therapist-patient, or other healthcare professional relationship between Amirsys Inc. ("Amirsys") and any recipient. This Product may not reflect the most current medical developments, and Amirsys makes no claims, promises, or guarantees about accuracy, completeness, or adequacy of the information contained in or linked to the Product. The Product is not a substitute for or replacement of professional medical judgment. Amirsys and its affiliates, authors, contributors, partners, and sponsors disclaim all liability or responsibility for any injury and/or damage to persons or property in respect to actions taken or not taken based on any and all Product information.

In the cases where drugs or other chemicals are prescribed, readers are advised to check the Product information currently provided by the manufacturer of each drug to be administered to verify the recommended dose, the method and duration of administration, and contraindications. It is the responsibility of the treating physician relying on experience and knowledge of the patient to determine dosages and the best treatment for the patient.

To the maximum extent permitted by applicable law, Amirsys provides the Product AS IS AND WITH ALL FAULTS, AND HEREBY DISCLAIMS ALL WARRANTIES AND CONDITIONS, WHETHER EXPRESS, IMPLIED OR STATUTORY, INCLUDING BUT NOT LIMITED TO, ANY (IF ANY) IMPLIED WARRANTIES OR CONDITIONS OF MERCHANTABILITY, OF FITNESS FOR A PARTICULAR PURPOSE, OF LACK OF VIRUSES, OR ACCURACY OR COMPLETENESS OF RESPONSES, OR RESULTS, AND OF LACK OF NEGLIGENCE OR LACK OF WORKMANLIKE EFFORT. ALSO, THERE IS NO WARRANTY OR CONDITION OF TITLE, QUIET ENJOYMENT, QUIET POSSESSION, CORRESPONDENCE TO DESCRIPTION OR NON-INFRINGEMENT, WITH REGARD TO THE PRODUCT. THE ENTIRE RISK AS TO THE QUALITY OF OR ARISING OUT OF USE OR PERFORMANCE OF THE PRODUCT REMAINS WITH THE READER.

Amirsys disclaims all warranties of any kind if the Product was customized, repackaged or altered in any way by any third party.

Library of Congress Cataloging-in-Publication Data

Diagnostic pathology. Lymph nodes and spleen with extranodal lymphomas / [edited by] L. Jeffrey Medeiros, MD, Professor and Chair, Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX.

p. ; cm.

Includes bibliographical references and index.

ISBN 978-1-931884-52-5

1. Lymphomas--Diagnosis--Handbooks, manuals, etc. 2. Lymph nodes--Diseases--Diagnosis--Handbooks, manuals, etc. 3. Spleen--Diseases--Pathogenesis--Handbooks, manuals, etc. 4. Lymphomas--Diagnosis--Atlases. 5. Lymph nodes--Diseases--Diagnosis--Atlases. 6. Spleen--Diseases--Pathogenesis--Atlases. I. Medeiros, L. Jeffrey, editor. II. Title: Lymph nodes and spleen with extranodal lymphomas.

[DNLM: 1. Lymphatic Diseases--diagnosis--Atlases. 2. Lymph Nodes--pathology--Atlases. 3. Lymphoma--diagnosis--Atlases. 4. Spleen--pathology--Atlases. WH 17]

RC280.L9D53 2011

616.99'446--dc22

2010051953

To the women in my life—my mother Albertina Medeiros, my sister Deborah Medeiros-Stroscio, my wife Carrie Medeiros, and our two precious girls Christina and Caroline.

To my first teacher of hematopathology—Professor Isao Katayama of Japan.

To the coauthors of this book—a marvelous group of colleagues who worked so very hard to complete this project.

LJM

CONTRIBUTING AUTHORS

Wesley O. Greaves, MD

Fellow

Department of Hematopathology
The University of Texas M. D. Anderson Cancer Center
Houston, TX

Wei Liu, MD, PhD

Fellow

Department of Hematopathology
The University of Texas M. D. Anderson Cancer Center
Houston, TX

Faisal Alseraye, MD

Fellow

Department of Hematopathology
The University of Texas M. D. Anderson Cancer Center
Houston, TX

Keyur Patel, MD, PhD

Assistant Professor

Department of Hematopathology
The University of Texas M. D. Anderson Cancer Center
Houston, TX

Sergej Konoplev, MD, PhD

Assistant Professor

Department of Hematopathology
The University of Texas M. D. Anderson Cancer Center
Houston, TX

James M. You, MD, PhD

Assistant Professor

Department of Hematopathology
The University of Texas M. D. Anderson Cancer Center
Houston, TX

DIAGNOSTIC PATHOLOGY



LYMPH NODES AND SPLEEN WITH EXTRANODAL LYMPHOMAS

Amirsys, creators of the highly acclaimed radiology series Diagnostic Imaging, proudly introduces its new Diagnostic Pathology series, designed as easy-to-use reference texts for the busy practicing surgical pathologist. Written by world-renowned experts, the series will consist of 15 titles in all the crucial diagnostic areas of surgical pathology.

The newest book in this series, *Diagnostic Pathology: Lymph Nodes and Spleen with Extranodal Lymphomas*, contains approximately 900 pages of comprehensive, yet concise, descriptions of more than 120 specific diagnoses. Amirsys's pioneering bulleted format distills pertinent information to the essentials. Each chapter has the same organization providing an easy-to-read reference for making rapid, efficient, and accurate diagnoses in a busy surgical pathology practice. A highlighted Key Facts box provides the essential features of each diagnosis. Detailed sections on Terminology, Etiology/Pathogenesis, Clinical Issues, Macroscopic and Microscopic Findings, and the all important Differential Diagnoses follow so you can find the information you need in the exact same place every time.

Most importantly, every diagnosis features numerous high-quality images, including gross pathology, H&E and immunohistochemical stains, correlative radiographic images, and richly colored graphics, all of which are fully annotated to maximize their illustrative potential.

We believe that this lavishly illustrated series, with its up-to-date information and practical focus, will become the core of your reference collection. Enjoy!

Elizabeth H. Hammond, MD
Executive Editor, Pathology
Amirsys, Inc.

Anne G. Osborn, MD
Chairman and Chief Executive Officer
Amirsys Publishing, Inc.

PREFACE

Most likely the reader has heard the lament, often said in jest, “All lymphomas look the same to me.” Indeed, lymphomas involving lymph nodes, spleen, and other extranodal sites present many diagnostic difficulties to the practicing pathologist.

Distinguishing benign from malignant lesions can be a challenge in and of itself, requiring histologic and often immunophenotypic analysis, as well as molecular studies in a subset of cases. Once the benign nature of a lesion is established, an etiology needs to be suggested. If the lesion is malignant, both hematopoietic and non-hematopoietic tumors must be identified as such. Even after a lesion is recognized as hematopoietic, the possibilities are vast and include neoplasms of B, T, NK, myeloid, and histiocytic lineage. Complicating matters further is the continuous evolution of the concepts and terminology of the field and the large amounts of data being generated via high throughput technologies. How does one sort and apply this information? What is needed to sign out cases, and what is not?

With these questions in mind, the shared goal of the authors in writing this text was to create a quick, easy-to-use reference. The contents of this volume include benign and malignant lesions of lymph node and spleen as well as extranodal lymphomas. The lymphomas are designated, in large part, using the terminology of the 2008 World Health Organization.

As is the style of the Diagnostic Pathology series, clinical and histologic features, the results of relevant ancillary studies, and a differential diagnosis for each entity are provided in an easy-to-read bulleted format. A Key Facts section captures essential aspects of the entity. References are recent and selected for relevance, rather than encyclopedic coverage. Images have been used generously and illustrate the typical and common variant features of each entity. We also have included standard protocols for the examination and reporting of lymphomas. Finally, the Amirsys eBook Advantage™ license included with each printed copy of this book provides fully searchable text and a complete listing of antibodies.

The authors hope that the reader will find *Diagnostic Pathology: Lymph Nodes and Spleen with Extranodal Lymphomas* to be a useful resource.

L. Jeffrey Medeiros, MD
Professor and Chair
Department of Hematopathology
The University of Texas M. D. Anderson Cancer Center
Houston, TX

ACKNOWLEDGMENTS

Text Editing

Ashley R. Renlund, MA
Arthur G. Gelsinger, MA
Matthew R. Connelly, MA
Lorna Moring, MS
Alicia M. Moulton

Image Editing

Jeffrey J. Marmorstone
Lisa A. Magar

Medical Text Editing

Carolyn J. Teman, MD, MS

Illustrations

Laura C. Sesto, MA
Lane R. Bennion, MS
Richard Coombs, MS

Art Direction and Design

Laura C. Sesto, MA

Assistant Editor

Dave L. Chance, MA

Publishing Lead

Kellie J. Heap



AMIRSYS®

Names you know. Content you trust.®

SECTIONS

Reactive Nonspecific Changes

Infectious Causes of Lymphadenitis

Reactive Lymphadenopathies

Hodgkin Lymphomas

Leukemia/Lymphoma of Immature B- or T-cell
Lineage

Nodal B-cell Lymphomas

Extranodal B-cell Lymphomas

“Gray Zone” B-cell Lymphomas

Nodal T-cell Lymphomas

Extranodal T-/NK-cell Lymphomas

Immunodeficiency-associated Lymphoproliferations

Non-Hematopoietic Proliferations in Lymph Node

Granulocytic/Histiocytic Tumors

Spleen

Antibody Index

TABLE OF CONTENTS

SECTION 1 Reactive Nonspecific Changes

Reactive Follicular Hyperplasia <i>C. Cameron Yin, MD, PhD</i>	1-2
Reactive Paracortical Hyperplasia <i>C. Cameron Yin, MD, PhD</i>	1-8

SECTION 2 Infectious Causes of Lymphadenitis

Chronic Granulomatous Lymphadenitis <i>C. Cameron Yin, MD, PhD</i>	2-2
Suppurative Lymphadenitis <i>C. Cameron Yin, MD, PhD</i>	2-10
Mycobacterium tuberculosis Lymphadenitis <i>Tariq Muzzafar, MBBS</i>	2-14
Atypical Mycobacterial Lymphadenitis <i>Tariq Muzzafar, MBBS</i>	2-22
Mycobacterial Spindle Cell Pseudotumor <i>Tariq Muzzafar, MBBS</i>	2-30
Cat Scratch Disease <i>Roberto N. Miranda, MD</i>	2-34
Bacillary Angiomatosis <i>Roberto N. Miranda, MD</i>	2-40
Lymphogranuloma Venereum Lymphadenitis <i>Roberto N. Miranda, MD</i>	2-46
Whipple Disease <i>Sa A. Wang, MD</i>	2-50
Syphilitic Lymphadenitis <i>Francisco Vega, MD, PhD</i>	2-54
Infectious Mononucleosis <i>Pei Lin, MD</i>	2-56
Histoplasma Lymphadenitis <i>Tariq Muzzafar, MBBS</i>	2-60
Cryptococcal Lymphadenitis <i>Tariq Muzzafar, MBBS</i>	2-64
Toxoplasma Lymphadenitis <i>Carlos E. Bueso-Ramos, MD, PhD</i>	2-68

Coccidioides Lymphadenitis <i>Tariq Muzzafar, MBBS</i>	2-74
Herpes Simplex Lymphadenitis <i>L. Jeffrey Medeiros, MD</i>	2-82
Cytomegalovirus Lymphadenitis <i>Sa A. Wang, MD</i>	2-86
Human Immunodeficiency Virus Lymphadenitis <i>Tariq Muzzafar, MBBS</i>	2-94

SECTION 3 Reactive Lymphadenopathies

Inflammatory Pseudotumor <i>Francisco Vega, MD, PhD</i>	3-2
Progressive Transformation of Germinal Centers <i>Pei Lin, MD</i>	3-8
Kikuchi-Fujimoto Disease <i>Carlos E. Bueso-Ramos, MD, PhD</i>	3-14
Rosai-Dorfman Disease <i>Faisal Alseraye, MD & L. Jeffrey Medeiros, MD</i>	3-24
Kimura Disease <i>C. Cameron Yin, MD, PhD</i>	3-30
Unicentric Hyaline Vascular Variant Castleman Disease <i>Pei Lin, MD</i>	3-38
Unicentric Plasma Cell Variant Castleman Disease <i>Pei Lin, MD</i>	3-44
Multicentric Castleman Disease <i>Pei Lin, MD</i>	3-50
Rheumatoid Arthritis-related Lymphadenopathy <i>L. Jeffrey Medeiros, MD</i>	3-58
Sarcoid Lymphadenopathy <i>Sa A. Wang, MD</i>	3-66
Dermatopathic Lymphadenopathy <i>Sa A. Wang, MD</i>	3-72
Hemophagocytic Lymphohistiocytosis <i>Sa A. Wang, MD</i>	3-78
Langerhans Cell Histiocytosis <i>Sa A. Wang, MD</i>	3-88

Lymphadenopathy Associated with Joint Prostheses <i>Roberto N. Miranda, MD</i>	3-100
Lipid-associated Lymphadenopathy <i>Tariq Muzzafar, MBBS</i>	3-106
Lymphadenopathy Secondary to Drug-induced Hypersensitivity Syndrome <i>Tariq Muzzafar, MBBS</i>	3-110

SECTION 4 Hodgkin Lymphomas

Nodular Lymphocyte Predominant Hodgkin Lymphoma <i>Pei Lin, MD</i>	4-2
Lymphocyte-rich Classical Hodgkin Lymphoma <i>Sa A. Wang, MD</i>	4-14
Nodular Sclerosis Hodgkin Lymphoma <i>C. Cameron Yin, MD, PhD</i>	4-22
Mixed Cellularity Hodgkin Lymphoma <i>C. Cameron Yin, MD, PhD</i>	4-32
Lymphocyte-depleted Hodgkin Lymphoma <i>C. Cameron Yin, MD, PhD</i>	4-38

Hodgkin Lymphoma Specimen Examination

Protocol for Examination of Hodgkin Lymphoma Specimens <i>L. Jeffrey Medeiros, MD</i>	4-44
------------------------------------------------------------------------------------------	------

SECTION 5 Leukemia/Lymphoma of Immature B- or T-cell Lineage

B-lymphoblastic Leukemia/Lymphoma <i>Carlos E. Bueso-Ramos, MD, PhD</i>	5-2
T-lymphoblastic Leukemia/Lymphoma <i>Carlos E. Bueso-Ramos, MD, PhD</i>	5-12
Lymphomas Associated with FGFR1 Abnormalities <i>Roberto N. Miranda, MD</i>	5-20

SECTION 6 Nodal B-cell Lymphomas

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma <i>Carlos E. Bueso-Ramos, MD, PhD</i>	6-2
Richter Syndrome <i>Sergej Konoplev, MD, PhD</i>	6-8
Lymphoplasmacytic Lymphoma and Waldenstrom Macroglobulinemia <i>Pei Lin, MD</i>	6-14

Nodal Marginal Zone B-cell Lymphoma <i>Pei Lin, MD</i>	6-24
Nodal Follicular Lymphoma <i>C. Cameron Yin, MD, PhD</i>	6-30
Mantle Cell Lymphoma <i>C. Cameron Yin, MD, PhD</i>	6-42
Mantle Cell Lymphoma, Blastoid Variant <i>C. Cameron Yin, MD, PhD</i>	6-46
Diffuse Large B-cell Lymphoma, NOS, Centroblastic <i>Francisco Vega, MD, PhD</i>	6-52
Diffuse Large B-cell Lymphoma, NOS, Immunoblastic <i>Francisco Vega, MD, PhD</i>	6-56
T-cell/Histiocyte-rich Large B-cell Lymphoma <i>Francisco Vega, MD, PhD</i>	6-62
ALK+ Diffuse Large B-cell Lymphoma <i>Tariq Muzzafar, MBBS</i>	6-66
EBV+ Diffuse Large B-cell Lymphoma of the Elderly <i>Tariq Muzzafar, MBBS</i>	6-72
Plasmablastic Lymphoma Arising in HHV8+ Multicentric Castlemans Disease <i>L. Jeffrey Medeiros, MD</i>	6-78
Burkitt Lymphoma <i>Carlos E. Bueso-Ramos, MD, PhD</i>	6-84

SECTION 7 Extranodal B-cell Lymphomas

Extranodal Marginal Zone B-cell Lymphoma (MALT Lymphoma) <i>Pei Lin, MD</i>	7-2
Extranodal Follicular Lymphoma <i>Roberto N. Miranda, MD</i>	7-12
Primary Cutaneous Follicle Center Lymphoma <i>Roberto N. Miranda, MD</i>	7-24
Primary Mediastinal (Thymic) Large B-cell Lymphoma <i>Francisco Vega, MD, PhD</i>	7-34
Primary Diffuse Large B-cell Lymphoma of the CNS <i>Tariq Muzzafar, MBBS</i>	7-44
Diffuse Large B-cell Lymphoma Associated with Chronic Inflammation <i>Wei Liu, MD, PhD & L. Jeffrey Medeiros, MD</i>	7-54
Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type <i>Sa A. Wang, MD</i>	7-60
Plasmablastic Lymphoma <i>Francisco Vega, MD, PhD</i>	7-68

Primary Effusion Lymphoma (PEL) and Solid Variant of PEL <i>Francisco Vega, MD, PhD</i>	7-78	Mycosis Fungoides <i>Sa A. Wang, MD</i>	10-36
Lymphomatoid Granulomatosis <i>Francisco Vega, MD, PhD</i>	7-86	Sezary Syndrome <i>Sa A. Wang, MD</i>	10-50
Intravascular Large B-cell Lymphoma <i>Francisco Vega, MD, PhD</i>	7-96	Primary Cutaneous Anaplastic Large Cell Lymphoma <i>C. Cameron Yin, MD, PhD</i>	10-60
Plasmacytoma <i>Pei Lin, MD</i>	7-102	Lymphomatoid Papulosis <i>C. Cameron Yin, MD, PhD</i>	10-66
		T-cell Prolymphocytic Leukemia Involving Lymph Node and Other Tissues <i>Tariq Muzzafar, MBBS & L. Jeffrey Medeiros, MD</i>	10-72

SECTION 8 "Gray Zone" B-cell Lymphomas

B-cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-cell Lymphoma and Burkitt Lymphoma <i>Carlos E. Bueso-Ramos, MD, PhD</i>	8-2
B-cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-cell Lymphoma and Classical Hodgkin Lymphoma <i>Francisco Vega, MD, PhD</i>	8-8

SECTION 9 Nodal T-cell Lymphomas

Peripheral T-cell Lymphoma, Not Otherwise Specified <i>James M. You, MD, PhD</i>	9-2
Angioimmunoblastic T-cell Lymphoma <i>Sa A. Wang, MD</i>	9-10
Adult T-cell Leukemia/Lymphoma, HTLV-1+ <i>Carlos E. Bueso-Ramos, MD, PhD & Roberto N. Miranda, MD</i>	9-20
ALK+ Anaplastic Large Cell Lymphoma <i>Francisco Vega, MD, PhD</i>	9-30
ALK- Anaplastic Large Cell Lymphoma <i>Francisco Vega, MD, PhD</i>	9-36

SECTION 10 Extranodal T-/NK-cell Lymphomas

Breast Implant-associated Anaplastic Large Cell Lymphoma <i>Roberto N. Miranda, MD</i>	10-2
Extranodal NK-/T-cell Lymphoma, Nasal Type <i>L. Jeffrey Medeiros, MD</i>	10-10
Enteropathy-associated T-cell Lymphoma <i>Sa A. Wang, MD</i>	10-18
Subcutaneous Panniculitis-like T-cell Lymphoma <i>Tariq Muzzafar, MBBS</i>	10-24
Primary Cutaneous Gamma-Delta T-cell Lymphoma <i>L. Jeffrey Medeiros, MD</i>	10-30

Non-Hodgkin Lymphoma Specimen Examination

Protocol for Examination of Non-Hodgkin Lymphoma Specimens <i>L. Jeffrey Medeiros, MD</i>	10-80
----------------------------------------------------------------------------------------------	-------

SECTION 11 Immunodeficiency-associated Lymphoproliferations

Overview of Lymphoproliferative Disorders Associated with Primary Immune Deficiency Disorders <i>Keyur Patel, MD, PhD</i>	11-2
Autoimmune Lymphoproliferative Syndrome <i>Sa A. Wang, MD</i>	11-8
Immunomodulating Agent-associated Lymphoproliferative Disorders <i>Tariq Muzzafar, MBBS</i>	11-20
Post-transplant Lymphoproliferative Disorder, Early Lesions and Polymorphic <i>C. Cameron Yin, MD, PhD & Pei Lin, MD</i>	11-28
Post-transplant Lymphoproliferative Disorder, Monomorphic <i>Pei Lin, MD & L. Jeffrey Medeiros, MD</i>	11-34

SECTION 12 Non-Hematopoietic Proliferations in Lymph Node

Epithelial Inclusions in Lymph Node <i>Roberto N. Miranda, MD</i>	12-2
Nevus Cell Inclusions in Lymph Node <i>Roberto N. Miranda, MD</i>	12-8
Vascular Transformation of Lymph Node Sinuses <i>Carlos E. Bueso-Ramos, MD, PhD</i>	12-12
Angiomyomatous Hamartoma <i>Carlos E. Bueso-Ramos, MD, PhD</i>	12-16
Palisaded Myofibroblastoma <i>L. Jeffrey Medeiros, MD</i>	12-20

Metastatic Kaposi Sarcoma	12-24	Classical Hodgkin Lymphoma	14-82
<i>Carlos E. Bueso-Ramos, MD, PhD</i>		<i>Francisco Vega, MD, PhD</i>	

SECTION 13 Granulocytic/Histiocytic Tumors

Myeloid/Monocytic Sarcoma	13-2
<i>Carlos E. Bueso-Ramos, MD, PhD</i>	
Blastic Plasmacytoid Dendritic Cell Neoplasm	13-10
<i>Wesley O. Greaves, MD & L. Jeffrey Medeiros, MD</i>	
Histiocytic Sarcoma	13-18
<i>Roberto N. Miranda, MD</i>	
Follicular Dendritic Cell Sarcoma	13-28
<i>Sa A. Wang, MD</i>	
Interdigitating Dendritic Cell Sarcoma	13-36
<i>Wesley O. Greaves, MD & L. Jeffrey Medeiros, MD</i>	
Langerhans Cell Sarcoma	13-42
<i>Sa A. Wang, MD</i>	
Mast Cell Disease	13-50
<i>Carlos E. Bueso-Ramos, MD, PhD</i>	
<i>Roberto N. Miranda, MD & L. Jeffrey Medeiros, MD</i>	

SECTION 14 Spleen

Splenic Inflammatory Pseudotumor	14-2
<i>Roberto N. Miranda, MD</i>	
Post-Chemotherapy Histiocyte-rich Pseudotumor of Spleen	14-10
<i>Roberto N. Miranda, MD</i>	
Inflammatory Pseudotumor-like Follicular Dendritic Cell Tumor	14-16
<i>Roberto N. Miranda, MD</i>	
Splenic Marginal Zone Lymphoma	14-22
<i>Roberto N. Miranda, MD</i>	
Hairy Cell Leukemia	14-30
<i>Roberto N. Miranda, MD</i>	
Hairy Cell Leukemia Variant	14-38
<i>Roberto N. Miranda, MD</i>	
Splenic Diffuse Red Pulp Small B-cell Lymphoma	14-46
<i>Roberto N. Miranda, MD</i>	
Diffuse Large B-cell Lymphoma Arising in the Spleen	14-52
<i>Roberto N. Miranda, MD</i>	
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	14-58
<i>Roberto N. Miranda, MD</i>	
Follicular Lymphoma	14-66
<i>Roberto N. Miranda, MD</i>	
Mantle Cell Lymphoma	14-74
<i>Roberto N. Miranda, MD</i>	

SECTION 15 Antibody Index

Antibody Index	15-2
----------------	------

Reactive Nonspecific Changes


Reactive Follicular Hyperplasia

1-2


Reactive Paracortical Hyperplasia

1-8

REACTIVE FOLLICULAR HYPERPLASIA



A hyperplastic lymphoid follicle is seen with a central, prominent germinal center and a peripheral, sharply demarcated mantle zone.



A reactive germinal center is composed of a mixed population of centrocytes, centroblasts, follicular dendritic cells, and tingible-body macrophages.

TERMINOLOGY

Abbreviations

- Reactive follicular hyperplasia (RFH)

Synonyms

- Follicular hyperplasia

Definitions

- Benign, reversible process characterized by marked proliferation of hyperplastic lymphoid follicles
 - Hyperplastic follicles have prominent germinal centers (so-called secondary follicles)
 - Characteristic of humoral immune reaction involving stimulation and proliferation of B cells
 - Usually involves lymph nodes but can affect extranodal organs

ETIOLOGY/PATHOGENESIS

Environmental Exposure

- Variety of drugs, chemicals, and environmental pollutants can cause RFH

Infectious Agents

- Most common cause of RFH is bacterial infection
 - Fungi, parasites, and viruses also can cause RFH, either pure or as part of mixed reactive pattern

Others

- In many cases, etiology of RFH cannot be identified

CLINICAL ISSUES

Presentation

- Patients typically present with enlarged lymph nodes, either localized or widespread
 - Systemic symptoms, such as fever, fatigue, and weight loss, may be present

- Laboratory abnormalities, such as leukocytosis, neutrophilia, or lymphocytosis, are common with infections and may be present
- Lymph node size is important
 - Small, shotty lymph nodes in asymptomatic patients are within normal limits
 - Lymph nodes ≥ 1 cm in diameter are abnormal
- Painful lymph nodes are more often related to inflammation or hemorrhage
- Age and duration are important in identifying etiology
- Location and consistency can suggest most likely etiologic agent
 - Location, as related to likely causes of lymphadenopathy
 - Cervical: Infectious mononucleosis
 - Posterior cervical: Toxoplasmosis
 - Parotid, submaxillary, epitrochlear: HIV infection
 - Cervical and axillary: Cat scratch disease
 - Inguinal: Sexually transmitted diseases
 - Supraclavicular: Often associated with malignant diseases, especially in older patients
 - Consistency, as related to likely causes of lymphadenopathy
 - Soft: Inflammatory
 - Fluctuant: Suppurative infection (often bacterial or fungal)
 - Matted: Tuberculosis, lymphogranuloma venereum, cancer
 - Firm to hard: Malignancy, including lymphoma or metastatic carcinoma

Treatment

- Localized lymph node enlargement in absence of other symptoms requires follow-up for 3-4 weeks
 - If lymphadenopathy does not resolve, additional investigation is likely needed
- Generalized lymphadenopathy usually requires immediate investigation for etiology

REACTIVE FOLLICULAR HYPERPLASIA

Key Facts

Terminology

- Benign, reversible process characterized by hyperplastic secondary lymphoid follicles

Clinical Issues

- Enlarged lymph nodes, localized or widespread
- \pm systemic symptoms: Fever, fatigue, weight loss
- Age and duration are important clues for etiology
- Lymph node size, location, and consistency can suggest likely etiologic agent

Microscopic Pathology

- Numerous enlarged follicles, varying in size and shape, with occasional coalescence of follicles
- Reactive follicles have central germinal centers and peripheral, sharply demarcated mantle zones

Ancillary Tests

- Germinal center and mantle zone B cells express polytypic Igs and pan-B markers
- Germinal center centrocytes and centroblasts are CD10(+), Bcl-6(+), and Bcl-2(-)
- No monoclonal *IgH* gene rearrangements
- No evidence of t(14;18)(q32;q21) or *IgH-BCL2* fusion sequences

Top Differential Diagnoses

- Follicular lymphoma
- Atypical follicular hyperplasia
- Progressive transformation of germinal centers
- Nodular lymphocyte predominant Hodgkin lymphoma
- Lymphocyte-rich classical HL, nodular variant

Prognosis

- Benign, reversible process with no impact on patient survival
 - Can be associated with other diseases such as autoimmune disease or malignancy

MICROSCOPIC PATHOLOGY

Histologic Features

- Numerous enlarged follicles, varying in size and shape, with occasional coalescence of follicles
 - In lymph nodes, reactive follicles usually prominent in cortex, with lesser involvement of other lymph node compartments
 - In spleen, reactive follicles are located in white pulp
- Reactive follicles: Have central germinal centers and peripheral, sharply demarcated mantle zones
- Germinal centers: Composed of centrocytes, centroblasts, follicular dendritic cells (FDC), T cells, and macrophages/histiocytes
- Centroblasts: 3-4x size of small lymphocytes with large vesicular nuclei, 1-3 peripheral nucleoli, frequent mitoses, and rim of cytoplasm
- Centrocytes: Smaller cells with cleaved nuclei, small nucleoli, rare mitoses, and scant cytoplasm
- Follicular dendritic cells: Few (~ 1%) have 2 square-shaped adjacent nuclei and long cytoplasmic processes
- Histiocytes: Have pale cytoplasm often containing apoptotic cellular debris (so-called tingible body macrophages)
 - Impart "starry sky" pattern when prominent
- Germinal centers: Usually organized into dark and light zones (a.k.a. polarization)
 - Dark zone contains many centroblasts and mitotic figures
 - Lymphocyte proliferation and somatic hypermutation of *IGH* gene occur in dark zone
 - Light zone contains predominantly centrocytes and follicular dendritic cells

- Centrocytes represent later stage of activation/maturation; interaction with T cells and FDCs occurs
- Mantle zones: Composed of concentric layers of small naive (not antigen-exposed) B lymphocytes
- In some cases, specific microorganisms can be detected in histologic sections
 - Common histochemical stains for this purpose: Acid-fast, PAS, GMS, Gram, and Warthin-Starry

Predominant Pattern/Injury Type

- Lymphoid, follicular

Predominant Cell/Compartment Type

- Lymphadenopathy

ANCILLARY TESTS

Immunohistochemistry

- Germinal center and mantle zone B cells express polytypic immunoglobulins and pan-B-cell antigens
- Germinal center centrocytes and centroblasts are CD10(+), Bcl-6(+), and Bcl-2(-)

Flow Cytometry

- Polytypic B-cell population; CD10(+), CD23(+/-), T-cell antigens(-)

PCR

- No monoclonal immunoglobulin heavy chain gene rearrangement by PCR
- No evidence of t(14;18)(q32;q21) or *IgH-BCL2* fusion sequences

DIFFERENTIAL DIAGNOSIS

Follicular Lymphoma (FL)

- Lymph node typically replaced by numerous follicles of similar size and shape (back to back)
- Neoplastic follicles composed of relatively monomorphic population of germinal center cells
- Neoplastic follicles often lack mantle zones

REACTIVE FOLLICULAR HYPERPLASIA

Differential Diagnosis: Reactive Follicular Hyperplasia (RFH) vs. Follicular Lymphoma (FL)

	Reactive Follicular Hyperplasia	Follicular Lymphoma
Size and shape of follicles	Variable	Similar, back to back
Germinal center cells	Heterogeneous	Monotonous
Tingible-body macrophages	Numerous	Few
Proliferation activity	High	Low
Mantle zone	Sharply demarcated	Absent
Capsule and perinodal invasion	Uncommon	Common
Surface Ig	Polytypic	Monotypic
Bcl-2	Negative	Positive ~ 80-90%
IgH gene rearrangement	Polyclonal	Monoclonal
t(14;18)(q32;q21)	Absent	Present ~ 80-90%

- Tingible-body macrophages are typically decreased compared with RFH
- Mitoses and proliferation rate (assessed by Ki-67) often lower in follicular lymphoma than in RFH
- Neoplastic follicles commonly invade lymph node capsule or extend into perinodal tissues
- Immunophenotyping is very helpful
 - FL cells usually express monotypic surface Ig and Bcl-2
 - Some cases of FL lack surface Ig; this is aberrant and supports lymphoma
- Molecular or cytogenetic studies are also helpful for FL diagnosis
 - Most cases of FL carry monoclonal *IgH* gene rearrangements
 - t(14;18)(q32;q21) or *IgH-BCL2* fusion sequences present in 80-90% of FL

Atypical Follicular Hyperplasia

- Term used for follicular lesions having some histologic features suggestive of FL
- Diagnosis is now uncommon with advent of immunophenotypic and molecular methods
 - Problem can be attributed to lack of fresh tissue for ancillary studies in some cases
- Patients require close clinical follow-up

Progressive Transformation of Germinal Centers (PTGC)

- Typically associated with RFH
- Nodules are 3-4x larger than reactive follicles
- Germinal center cells are Bcl-2(-)

Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)

- Nodules are typically much larger than reactive follicles
- Neoplastic L&H cells are CD20(+), CD45(+), Bcl-2(-)
- Small cells in tumor nodules are mostly reactive B cells
- CD57(+) T cells are increased in nodules; T cells can form rosettes around LP cells

Lymphocyte-rich Classical HL

- Nodular variant can closely resemble NLPHL

- Neoplastic cells are typically CD15(+), CD30(+), CD20(-/+), and CD45(-)
- Small reactive follicles can often be observed within neoplastic nodules

SELECTED REFERENCES

1. Ioachim HL et al: Reactive lymphoid hyperplasia. In: Ioachim's Lymph Node Pathology. Philadelphia: Lippincott Williams & Wilkins. 172-80, 2008
2. Shimabukuro-Vornhagen A et al: Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials. *J Clin Oncol.* 23(24):5739-45, 2005
3. Lin P et al: The activation profile of tumour-associated reactive T-cells differs in the nodular and diffuse patterns of lymphocyte predominant Hodgkin's disease. *Histopathology.* 44(6):561-9, 2004
4. Chang CC et al: Follicular hyperplasia, follicular lysis, and progressive transformation of germinal centers. A sequential spectrum of morphologic evolution in lymphoid hyperplasia. *Am J Clin Pathol.* 120(3):322-6, 2003
5. Nguyen PL et al: Progressive transformation of germinal centers and nodular lymphocyte predominance Hodgkin's disease: a comparative immunohistochemical study. *Am J Surg Pathol.* 23(1):27-33, 1999
6. Osborne BM et al: Clinical implications of nodal reactive follicular hyperplasia in the elderly patient with enlarged lymph nodes. *Mod Pathol.* 4(1):24-30, 1991
7. van der Valk P et al: The histology of reactive lymph nodes. *Am J Surg Pathol.* 11(11):866-82, 1987
8. Nathwani BN et al: Morphologic criteria for the differentiation of follicular lymphoma from florid reactive follicular hyperplasia: a study of 80 cases. *Cancer.* 48(8):1794-806, 1981